使用锆 89（89Zr；半衰期 ~ 78.41 h）标记的前列腺特异性膜抗原 (PSMA) 靶向放射性示踪剂的正电子发射断层扫描/计算机断层扫描 (PET/CT) 在定位前列腺癌 (BCR) 的生化复发方面显示出希望对 38 名连续接受 [89Zr]Zr-PSMA-617 PET/CT 阴性 [68Ga] 的 BCR 男性（中位[最小-最大]前列腺特异性抗原 0.52 (0.12-2.50 ng/mL)）进行回顾性分析Ga-PSMA-11 PET/CT。注射后 1 小时、24 小时和 48 小时的 [89Zr]Zr-PSMA-617 示踪剂活性中位数为 123 (84) -166) MBq.[89Zr]Zr-PSMA-617 PET/CT 总共检测到 57 个病变：30/38 名 BCR (78%) 且先前常规 PSMA PET 呈阴性的男性中有 18 个局部复发、33 个淋巴结转移、6 个骨转移/CT。病变摄取从 1 小时显着增加到 24 小时，并且在大多数情况下，从 24 小时到 48 小时，肿瘤与背景的比率随着时间的推移显着增加，绝对增加 100 或更多。 。没有发现副作用。在基于 [89Zr]Zr-PSMA-617 PET/CT 的治疗后，所有患者的前列腺特异性抗原浓度均下降，三分之一的患者检测不到。回顾性、单中心设计；不频繁的组织病理学和影像学验证。这个大型系列提供了进一步的证据，证明 [89Zr]Zr-PSMA-617 PET/CT 是定位早期 BCR 的有益成像方式。随着时间的推移，肿瘤与背景的比率显着增加，从而可以定位传统 PSMA PET/CT 上未识别的肿瘤。© 2024。作者。

Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.Retrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.retrospective, single center design; infrequent histopathological and imaging verification.This large series provides further evidence that [89Zr]Zr-PSMA-617 PET/CT is a beneficial imaging modality to localize early BCR. A remarkable increase in tumor-to-background ratio over time allows localization of tumor unidentified on conventional PSMA PET/CT.© 2024. The Author(s).